ADVFN - Advanced Financial Network.
HOME» NASDAQ » N » NUVA Stock Price » NUVA Stock News

Nuvasive Share News

 Nuvasive (mm) Stock Price
NUVA Stock Price
 Nuvasive (mm) Stock Chart
NUVA Stock Chart
 Nuvasive (mm) Stock News
NUVA Stock News
 Nuvasive (mm) Company Information
NUVA Company Information
 Nuvasive (mm) Stock Trades
NUVA Stock Trades

NuVasive 2Q Earnings Surge Despite Sector Concerns

By Jon Kamp Of DOW JONES NEWSWIRES NuVasive Inc.'s (NUVA) second-quarter earnings more than doubled behind surging sales as the maker of devices for spinal-fusion surgery continued to shake off challenging market conditions seen by competitors. The San Diego-based company boosted its full-year earnings guidance Tuesday, raised the lower end of its sales forecast and maintained its outlook for sales growth next year. Shares rose 2.8%, to $35.00 in after-hours trading. Reports last week from Johnson & Johnson (JNJ) and Stryker Corp. (SYK) added to signs the $8 billion to $9 billion spinal-device market is facing pressure on product prices and procedure volumes that is restraining growth. But NuVasive, which markets tools for a unique procedure the company says cuts blood loss and hospital stays, has managed to maintain its high-growth pace by taking market share. NuVasive posted second-quarter earnings of $6.7 million, or 17 cents per share, up from $2.8 million, or 7 cents, a year ago. Excluding stock-based compensation and other costs, it said earnings were 42 cents in the recent quarter. Sales rose 35%, to $119.6 million. Analysts surveyed by Thomson Reuters had forecast, on average, earnings of 29 cents a share on sales of $117.7 million. Looking ahead, the company said it now expects full-year sales of $485 million to $500 million, with the bottom end of that range up $5 million from the prior forecast. It forecast earnings excluding items of $1.50 to $1.64 per share, compared with the prior $1.13 to $1.25 per share forecast. Analysts had forecast full-year earnings of $1.21 per share on sales of $490.3 million. Alex Lukianov, NuVasive's chairman and chief executive, said on a conference call that the company continues to expect sales growth of 25% to 30% next year. He also said, as he has before, that product innovations could fuel faster growth. -By Jon Kamp, Dow Jones Newswires; 617-654-6728;

Stock News for Nuvasive (NUVA)
03/29/201709:00:00NuVasive Receives First-Ever FDA Clearance For Cervical Interbody...
03/20/201709:00:00New Evidence-Based Recommendation Released From NICE (U.K.) For...
03/09/201718:04:25Statement of Changes in Beneficial Ownership (4)
03/03/201717:58:54Statement of Changes in Beneficial Ownership (4)
03/03/201717:53:21Statement of Changes in Beneficial Ownership (4)
03/02/201717:34:00NuVasive to Participate in Investor Events in March 2017
02/27/201714:23:16Statement of Ownership (sc 13g)
02/16/201717:58:21Statement of Changes in Beneficial Ownership (4)
02/15/201717:59:10Statement of Changes in Beneficial Ownership (4)
02/13/201718:31:20Annual Statement of Changes in Beneficial Ownership (5)
02/13/201717:31:22Amended Statement of Ownership (sc 13g/a)
02/10/201717:58:50Statement of Changes in Beneficial Ownership (4)
02/10/201717:57:56Statement of Changes in Beneficial Ownership (4)
02/10/201717:57:28Statement of Changes in Beneficial Ownership (4)
02/10/201717:55:18Statement of Changes in Beneficial Ownership (4)
02/10/201717:53:31Statement of Changes in Beneficial Ownership (4)
02/10/201717:53:06Statement of Changes in Beneficial Ownership (4)
02/10/201717:50:54Statement of Changes in Beneficial Ownership (4)
02/10/201717:49:59Statement of Changes in Beneficial Ownership (4)
02/10/201717:45:56Statement of Changes in Beneficial Ownership (4)

Nuvasive and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations